Corcept President logs option exercises and sales under 10b5-1 plan

Q: What are Sean Maduck’s direct CORT holdings after the transactions?

Direct holdings were 7,904 shares after the reported sales and exercises.

Q: How many CORT options remain after these exercises?

The $5.05 option shows 0 remaining; 281,986 options at $8.27 remain, fully exercisable, expiring 02/10/2027.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) insider activity: President Sean Maduck reported option exercises and open‑market sales on 10/01/2025 under a Rule 10b5‑1 plan. He exercised 1,986 stock options at $5.05 and 18,014 at $8.27, then sold 959 shares at a weighted average price of $83.7344, 16,394 at $85.0562, and 2,647 at $85.5758.

Following these transactions, direct holdings were 7,904 shares. Indirect holdings were 59,717 shares held by the Sean and Molly Maduck Living Trust, 40,000 by the SNM 2025 Grantor Retained Annuity Trust, and 10,000 by Duckhill Capital, LLC.

In Table II, the $5.05 option was fully exercised with 0 remaining, and 281,986 options at an exercise price of $8.27 remain outstanding, fully exercisable and expiring on 02/10/2027.

Insider Trade Summary

Net Seller: 20,000 shares ($1,701,232)

Net Sell 10 txns

Insider Maduck Sean

Role See Remarks

Sold 20,000 shs ($1.70M)

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy)	1,986	$0.00	--
Exercise	Stock option (right to buy)	18,014	$0.00	--
Exercise	Common Stock	1,986	$5.05	$10K
Exercise	Common Stock	18,014	$8.27	$149K
Sale	Common Stock	959	$83.7344	$80K
Sale	Common Stock	16,394	$85.0562	$1.39M
Sale	Common Stock	2,647	$85.5758	$227K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock option (right to buy) — 0 shares (Direct); Common Stock — 9,890 shares (Direct); Common Stock — 59,717 shares (Indirect, See Footnote)

Footnotes (1)

Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.23 to $84.16 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.41 to $85.40 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.41 to $85.79 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Fully exercisable.

Form 4 Insider Transactions: What Each Field Means →

10/03/2025 - 05:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Maduck Sean

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

94065

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2025		M		1,986	A	$5.05	9,890⁽¹⁾	D
Common Stock	10/01/2025		M		18,014	A	$8.27	27,904⁽¹⁾	D
Common Stock	10/01/2025		S⁽²⁾		959	D	$83.7344⁽³⁾	26,945⁽¹⁾	D
Common Stock	10/01/2025		S⁽²⁾		16,394	D	$85.0562⁽⁴⁾	10,551⁽¹⁾	D
Common Stock	10/01/2025		S⁽²⁾		2,647	D	$85.5758⁽⁵⁾	7,904⁽¹⁾	D
Common Stock								59,717	I	See Footnote⁽⁶⁾
Common Stock								40,000	I	See Footnote⁽⁷⁾
Common Stock								10,000	I	See Footnote⁽⁸⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$5.05	10/01/2025		M			1,986	⁽⁹⁾	05/02/2026	Common Stock	1,986	$0.00	0	D
Stock option (right to buy)	$8.27	10/01/2025		M			18,014	⁽⁹⁾	02/10/2027	Common Stock	18,014	$0.00	281,986	D

Explanation of Responses:

1. Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025 and 228 underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $83.23 to $84.16 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $84.41 to $85.40 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $85.41 to $85.79 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

6. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

7. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.

8. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

9. Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CORT’s President report on Form 4?

He exercised 1,986 options at $5.05 and 18,014 at $8.27, then sold 959, 16,394, and 2,647 shares at weighted average prices disclosed.

Were the trades under a Rule 10b5-1 plan for CORT?

Yes. The filing indicates transactions pursuant to a Rule 10b5-1 plan adopted on September 5, 2024.

What are Sean Maduck’s direct CORT holdings after the transactions?

Direct holdings were 7,904 shares after the reported sales and exercises.

What indirect CORT holdings were reported?

Indirect holdings were 59,717 shares (Living Trust), 40,000 (SNM 2025 GRAT), and 10,000 (Duckhill Capital, LLC).

How many CORT options remain after these exercises?

The $5.05 option shows 0 remaining; 281,986 options at $8.27 remain, fully exercisable, expiring 02/10/2027.

At what prices were CORT shares sold?

Weighted average sale prices were $83.7344, $85.0562, and $85.5758 for the respective blocks sold on 10/01/2025.